Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-26

Clinical Trial Update: A Study of LY2127399 in Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study of Eli Lilly's LY2127399 in rheumatoid arthritis was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY2127399 (dacetuzumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2018-04-26